DUPIlumab Dose REDUCtion in Patients With Controlled Atopic Eczema (DUPI REDUCE)
Atopic Dermatitis, Atopic Dermatitis Eczema
About this trial
This is an interventional treatment trial for Atopic Dermatitis focused on measuring Dupilumab
Eligibility Criteria
Inclusion Criteria: The subject is an adult, Has a diagnosis of AE, Receives dupilumab 300 mg q2w for the treatment of AE, Has controlled disease according to the Treat-to-Target criteria, Agrees to the possibility that the dosage of dupilumab will be lowered, Has voluntarily signed and dated an informed consent prior to any study related procedure. Exclusion Criteria: The subjects uses or initiates another systemic immunomodulating therapy for AE or another diagnosis.
Sites / Locations
- Amsterdam University Medical CentersRecruiting
- Erasmus Medical Center
Arms of the Study
Arm 1
Arm 2
Arm 3
Active Comparator
Experimental
Experimental
Dupilumab 300 mg q2w
Dupilumab 300 mg q3w
Dupilumab 300 mg q4w
Dupilumab s.c. 300 mg every 2 weeks for 24 weeks.
Dupilumab s.c. 300 mg every 3 weeks for 24 weeks.
Dupilumab s.c. 300 mg every 4 weeks for 24 weeks.